title: Antihyperglycemic and antihyperlipidemic activities of 2-(4-[(2-hydroxybenzyl) amino]-phenyl amino-methyl)-phenol in STZ induced diabetic rats.
abstract: Oral administration of 2-(4-[(2-hydroxybenzyl) amino]-phenyl amino-methyl)-phenol (HBPMP) (30 mg/kg) to Streptozotocin (STZ) rats produced significant antidiabetic activity after 6 h of HBPMP administration. Treatment of the STZ rats with HBPMP (30 mg/kg/day) for 30 days resulted in a significant decrease in their Fasting Blood Glucose (FBG), Serum Total Cholesterol (TC), Low Density Lipoprotein-Cholesterol (LDL-C), Very Low Density Lipoprotein-Cholesterol (VLDL-C) and triglycerides (TG) along with an increase in serum High Density Lipoprotein-Cholesterol (HDL-C) levels. Activities of Serum Aspartate transaminase (AST), Alanine transaminase (ALT) and Alkaline phosphatase (ALP) and levels of blood urea and creatinine were improved to near normal levels in the treated STZ rats indicating the protective role of the HBPMP against liver and kidney damage and its non-toxic property. In conclusion, HBPMP possesses antihyperglycemic and antihyperlipidemic activities.
authors.affiliation: Department of Biochemistry, Sri Venkateswara University, Tirupati, Andhra Pradesh 517 502, India.
authors.forename: Swapna
authors.initials: S
authors.lastname: Sirasanagandla
authors.forename: Ramesh Babu
authors.initials: RB
authors.lastname: Kasetti
authors.forename: Abdul Nabi
authors.initials: AN
authors.lastname: Shaik
authors.forename: Rajesh
authors.initials: R
authors.lastname: Natava
authors.forename: Venkata Prasad
authors.initials: VP
authors.lastname: Surtineni
authors.forename: Suresh Reddy
authors.initials: SR
authors.lastname: Cirradur
authors.forename: Apparao
authors.initials: A
authors.lastname: Chippada
mesh_terms: D000388:Air; D000814:Aniline Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004355:Drug Stability; D004952:Esters; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D019800:Phenol / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D010636:Phenols / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: C586653:2-(4-((2-hydroxybenzyl)amino)-phenylamino-methyl)-phenol; D000814:Aniline Compounds; D001786:Blood Glucose; D004952:Esters; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D010636:Phenols; D019800:Phenol
keywords: HBPMP; Hypoglycemic activity; Hypolipidemic; STZ